Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?

被引：15

作者：

Dunne, Eileen M. ^{[1
]}

Cilloniz, Catia ^{[2
,3
]}

von Mollendorf, Claire ^{[4
,5
]}

Lewnard, Joseph ^{[6
,7
,8
]}

Grant, Lindsay R. ^{[1
]}

Slack, Mary P. E. ^{[9
]}

Jodar, Luis ^{[1
]}

Theilacker, Christian ^{[1
]}

Gessner, Bradford D. ^{[1
]}

机构：

[1] Pfizer Vaccines, Collegeville, PA 19426 USA

[2] Continental Univ, Fac Hlth Sci, Huancayo, Peru

[3] Hosp Clin Barcelona, Dept Pneumol, Barcelona, Spain

[4] Murdoch Childrens Res Inst, Infect & Immun, Parkville, Vic, Australia

[5] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia

[6] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA USA

[7] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA USA

[8] Univ Calif Berkeley, Coll Engn, Ctr Computat Biol, Berkeley, CA USA

[9] Griffith Univ, Sch Med & Dent, Gold Coast Campus, Gold Coast, Qld, Australia

来源：

ARCHIVOS DE BRONCONEUMOLOGIA | 2023年 / 59卷 / 03期

关键词：

Streptococcus pneumoniae; Pneumococcal disease; Vaccines; 23-Valent pneumococcal polysaccharide; vaccine (PPV23) and 13-valent; pneumococcal conjugate vaccine (PCV13); Pneumonia; CONJUGATE VACCINE; UPDATED RECOMMENDATIONS; POLYSACCHARIDE VACCINE; ADVISORY-COMMITTEE; PREVENTION; PNEUMONIA;

D O I：

10.1016/j.arbres.2022.12.015

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Introduction: Fifteen and 20-valent pneumococcal conjugate vaccines (PCV15; PCV20) were recently licensed to prevent pneumococcal disease in adults. In the absence of efficacy or effectiveness data for these new vaccines, studies comparing 23-valent pneumococcal polysaccharide vaccine (PPV23) and PCV13 might help inform decision-making on how to best implement expanded-valency PCVs. Comparing PPV23 and PCV13 is problematic, as no head-to-head clinical trials evaluated efficacy. Comparing effectiveness results across observational studies that vary by population, design, and outcomes is difficult. To address these limitations, we undertook a narrative review of studies that assessed PPV23 and PCV13 vaccine effectiveness (VE) in the same adult populations.Methods: We conducted a literature search in PubMed and Google Scholar and screened 525 studies using a standardized evaluation framework.Results: Nine studies met inclusion criteria, all from high-income countries. None evaluated invasive pneumococcal disease (IPD) alone. VE against vaccine-type pneumococcal pneumonia ranged from 2 to 6% for PPV23 and 41 to 71% for PCV13. VE against pneumococcal pneumonia or severe pneumococcal disease (IPD or pneumococcal pneumonia) ranged from -10 to 11% for PPV23, 40 to 79% for PCV13, and 39 to 83% for sequential PCV13/PPV23. VE against all-cause pneumonia or lower respiratory tract infection ranged from -8 to 3% for PPV23 and 9 to 12% for PCV13.Conclusions: Overall, PCV13 demonstrated better protection than PPV23 against pneumococcal disease and all-cause respiratory outcomes in the included studies. Where evaluated, sequential PCV13/PPV23 vaccination showed little benefit over PCV13 alone. Results support the use of PCVs to protect against pneumococcal disease and respiratory infections in adults. (c) 2023 The Author(s). Published by Elsevier Espana, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

引用

页码：157 / 164

页数：8

共 40 条

[1]

[Anonymous], 2001, about us

[2] A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population [J].